Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 16, 2018. The document serves as a transaction notification regarding a specific equity award to a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single corporate transaction rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a conditional award of 11,800 Ordinary Shares (25 pence each) to Mrs. V A Whyte, the Company Secretary, under the 2017 Performance Share Plan. The transaction occurred on February 14, 2018, at a price of £12.908 per share. Vesting is subject to meeting performance criteria over a three-year period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The only noted condition is the performance-based vesting requirement attached to the share award.
Investor Verification Checklist
- Verify the vesting schedule and specific performance criteria for the 2017 Performance Share Plan.
- Confirm the total number of shares awarded to the Company Secretary and the associated valuation.
- Review the company's broader 20-F annual report for comprehensive financial performance data not included in this transaction notice.